Wells Fargo’s Amicus Therapeutics FOLD Stock Holding History

Wells Fargo’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,000	Closed	-$31K	–	6399
2018 Q1	$31K	Hold	45,000	–	–	﹤0.01%	5708
2017 Q4	$105K	Buy	+45,000	New	+$618K	﹤0.01%	5286
2017 Q1	–	Sell	-24,000	Closed	-$49K	–	6361
2016 Q4	$49K	Hold	24,000	–	–	﹤0.01%	5375
2016 Q3	$31K	Buy	+24,000	New	+$162K	﹤0.01%	5478

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Wells Fargo's FOLD Position: Q2 2026 in Review

Wells Fargo sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 111,070 shares — an estimated $1.61M sold.

Wells Fargo first reported a position in FOLD in Q2 2013 and held it in 47 quarters. The position peaked at $42.5M in Q1 2018. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Wells Fargo reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Wells Fargo sold 111,070 Amicus Therapeutics shares in Q2 2026, an estimated $1.61M.
Wells Fargo first reported a position in Amicus Therapeutics in Q2 2013 and held it in 47 quarters.
Wells Fargo's Amicus Therapeutics position peaked at $42.5M in Q1 2018.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.